Biocryst Pharmaceuticalsincis A Biotechnology Company Based In Durhamnorth Carolinaspecializing In Therapies For Rare Diseasesfounded In 1986The Company Utilizes Structure Guided Drug Designintegrating Biologycrystallographymedicinal Chemistryand Computational Modeling To Create Small Molecule And Protein Therapeutics The Company Focuses On Developing Oral And Injectable Therapies For Rare And Infectious Diseasesparticularly Through Enzyme Inhibition To Address Disease Mechanismsbiocryst S Approved Products Include Orladeyoafor Hereditary Angioedema Preventionrapivabafor Influenza Treatmentand Zokinvyafor Progeroid Laminopathiesits Pipeline Features Candidates Like Bcx10013 For Complement Mediated Diseases With A Revenue Of $1 3 Billion In 2023 And A Commitment To Research And Developmentbiocryst Aims To Expand Its Global Presence And Continue Innovating In The Rare Disease Spacethe Company Collaborates With Specialty Healthcare Providers And Rare Disease Communities To Meet Unmet Medical Needs
